Cabozantinib-S-Malate
This page contains brief information about cabozantinib-s-malate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
US Brand Name(s)
Cabometyx
Cometriq
Cometriq
FDA Approved
Yes
Use in Cancer
Cabozantinib-s-malate is approved to treat:
- Medullary thyroid cancer that is progressive and has metastasized (spread to other parts of the body). This use is approved for the Cometriq brand of cabozantinib-s-malate.
- Renal cell carcinoma (a type of kidney cancer) that is advanced. It is used in patients who have already received angiogenesis inhibitor therapy. This use is approved for the Cabometyx brand of cabozantinib-s-malate.
Cabozantinib-s-malate is also being studied in the treatment of other types ofcancer.
More About Cabozantinib-S-Malate
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Cabozantinib-S-Malate - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Targeted Cancer Therapies - Information about the use of this drug to treat cancer.
Clinical Trials Accepting Patients
Find Clinical Trials for Cabozantinib-s-malate - Check for trials from NCI's list of cancer clinical trials now accepting patients.
Cabozantinib-S-Malate - National Cancer Institute
.png)
No hay comentarios:
Publicar un comentario